EGFR and non-small cell lung carcinoma: EGFR mutations are seen in ~13% of patients with non-small cell lung cancer (NSCLC) in the United States [3], with a higher incidence in Japanese patients [4], and contribute to the pathogenesis of affected lung tumors.